Cashen Named Interim IRB Executive Chair

Published on October 11, 2018

We are delighted to announce Amanda Cashen, MD, has agreed to take on the interim role of Institutional Review Board (IRB) Executive Chair for Washington University, effective October 15, 2018. Amanda will replace Jonathan Green, MD, who left the University last month and served as Executive Chair since 2010.

Dr. Cashen, Associate Professor of Medicine in the Division of Oncology, Section of Stem Cell Transplant/Leukemia, has extensive experience in the conduct of clinical trials of novel therapies for leukemias and lymphomas, and collaborates with translational researchers as the principal investigator of the Lymphoid Malignancies Banking Protocol. She earned a B.S. in Molecular Biophysics and Biochemistry from Yale University, M.D. from Washington University, and completed her training in Internal Medicine and Hematology/Medical Oncology at Washington University/Barnes-Jewish Hospital. Amanda’s clinical practice focuses on the care of patients with hematologic malignancies, including stem cell transplant and cellular immunotherapies.

Amanda has been a member of the Washington University IRB for over ten years, and since 2011 has chaired one of the weekly IRB protocol review meetings. She is also a member of the IRB’s Protocol Adherence Review Committee. As Interim Executive Chair, Amanda will hold leadership responsibility for IRB review and approval of human subject research in accordance with current guidelines, institutional policies, and federal and state regulations governing human subject protections.

Please join us in congratulating Amanda in her new role.​

Sincerely,
Jennifer K. Lodge, PhD
Vice Chancellor for Research

Michael Kass, MD
Senior Associate Dean for Human Research Protection